<DOC>
	<DOCNO>NCT01943682</DOCNO>
	<brief_summary>The purpose study test safety study drug call CPX-351 . This drug test adult yet child adolescent . This study test different dos drug see dose safe child adolescent . Patients blood cancer ask take part study . Blood cancer may include leukemia lymphoma . Patients able study already treat standard chemotherapy disease disease still grow come back . CPX-351 drug yet approve United States Food Drug Administration ( FDA ) use research study like one . CPX-351 make two chemotherapy drug patient may already receive call cytarabine daunorubicin package together . Another purpose study collect blood sample special research study . Researchers want study much CPX-351 body time . These study call pharmacokinetic study PK study short . PK study require collection several blood sample participant give study drug .</brief_summary>
	<brief_title>Safety Study CPX-351 Children With Relapsed Leukemia Lymphoma</brief_title>
	<detailed_description>Cytarabine combination anthracycline frequently use chemotherapy platform newly diagnose relapsed/refractory acute myeloid leukemia ( AML ) hematologic malignancy . Synergistic antitumor activity demonstrate cytarabine daunorubicin dependent upon ratio drug best therapeutic effect observe cytarabine daunorubicin ratio 5:1 vitro vivo model . CPX-351 liposomal preparation cytarabine daunorubicin maintain therapeutic drug ratio 24 hour post infusion . The altered biodistribution encapsulation may result great therapeutic effect patient relapse hematologic malignancy demonstrate great tolerability non-liposomal cytarabine daunorubicin . This single institution phase-I pilot study aim assess pharmacokinetics , toxicity tolerability CPX-351 pediatric young adult relapsed/refractory hematologic malignancy . Subjects receive single course CPX-351 administer Days 1 , 3 , 5 . The study first open child dose exploration phase , available expand cohort , open child young adult tolerable dose determine .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Burkitt Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Lymphoma , Large-Cell , Anaplastic</mesh_term>
	<criteria>Age 1 . 12 month 21 year time enrollment dose exploration phase 2 . 12 month 30 year time enrollment expand phase Diagnosis : Patients must diagnosis hematologic malignancy ( acute myeloid leukemia ( AML ) , acute lymphoblastic leukemia ( ALL ) , aggressive lymphoma . Disease Status 1 . Acute myeloid leukemia patient nontherapy related AML must first great relapse refractory disease least two course induction therapy . 2 . Acute lymphoid leukemia patient ALL must second great relapse relapse disease refractory reinduction therapy . 3 . Aggressive Lymphoma patient must relapse refractory disease know curative therapy available . Patients must measurable disease CT scan . Performance status : Karnofsky &gt; = 50 % Lansky &gt; = 50 . Prior therapy : Patients must fully recover acute toxicity prior therapy . 1 . Hematopoetic Stem cell transplant ( HSCT ) : Patients relapse HSCT , eligible provide evidence active graft versus host disease ( GVHD ) least 2 month posttransplant . 2 . Anthracycline exposure : Patients previously TBI ( total body irradiation ) must total previous cumulative anthracycline exposure ≤ 450 mg/m2 daunorubicin equivalent . Patients prior TBI radiation mediastinum must previous cumulative anthracycline exposure e ≤ 300 mg/m2 daunorubicin equivalent . 3 . Cytotoxic therapy : 1 . AML Lymphoma : least 14 day must elapse since completion systemic cytotoxic therapy , exception hydroxyurea . 2 . ALL : patient relapse receive standard maintenance therapy wait period . At least 14 day must elapse since receive systemic cytarabine anthracycline/anthracenedione . 3 . Intrathecal cytotoxic therapy : waiting period require patient receive intrathecal cytarabine , methotrexate and/or hydrocortisone . At least 14 day must elapse since receive liposomal cytarabine intrathecal injection . Organ function requirement 1 . Adequate bone marrow function platelet count &gt; /= 20,000/uL ( may receive platelet transfusion ; Hemoglobin &gt; /= 8 g/dL ( may receive red blood cell transfusion ) 2 . Adequate Renal function maximum serum creatinine base age/gender . Subjects meet eligibility criterion base upon serum creatinine may meet eligibility criterion base upon 24 hour creatinine clearance radioisotope determine GFR &gt; /= 70 mL/min/1.73 m2 . 3 . Adequate liver function Direct bilirubin &lt; /= 1.5 x upper limit normal ( ULN ) age SGPT ( ALT ) &lt; 5.0 x upper limit normal ( ULN ) age institution ( unless elevation relate leukemia involvement ) . 4 . Adequate cardiac function Shortening fraction &gt; /= 27 % echocardiogram , Ejection fraction &gt; /= 50 % gate radionuclide study echocardiogram . 5 . Central Nervous system function patient seizure disorder may enrol anticonvulsant well control CNS toxicity &lt; /= Grade 2 . Patients follow diagnosis eligible : acute promyelocytic leukemia ( APML ) , Down Syndrome , Fanconi Anemia , acute lymphoblastic leukemia central nervous system leukemia ( CNS status 3 ) , Wilson 's disease Pregnant breastfeeding woman . Males female reproductive potential may participate unless agree use effective method contraception . Concomitant medication 1 . Growth factor growth factor support platelet white cell number function must administer within 7 day prior enrollment . 2 . Investigational drug patient currently receive another investigational drug eligible . 3 . Anticancer agent patient currently receive anticancer agent eligible exception intrathecal cytarabine oral hydroxyurea . Hydroxyurea must discontinue 24 hour prior initiation protocol therapy . Infection : Patients uncontrolled infection eligible . Patients opinion investigator may able comply safety monitoring requirement study eligible . History Wilson 's disease coppermetabolism disorder Major surgery within 4 week enrollment . Greater 13.6 Gy prior radiation mediastinum</criteria>
	<gender>All</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Relapsed acute myeloid leukemia</keyword>
	<keyword>non-therapy related acute myeloid leukemia</keyword>
	<keyword>Refractory acute myeloid leukemia</keyword>
	<keyword>Untreated acute myeloid leukemia</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>Leukemia</keyword>
</DOC>